Physician profile
Toby A Hampton
NPI 1831192699
$1,199.15
in general payments reported to CMS, 2019-2025
11 companies · $892 in 2025
The $892 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $79.56 · 2024: $227 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $525.45 | 2025 | Caplyta |
| Abbvie INC. | $208.56 | 2024-2025 | |
| Abbott Laboratories | $134.93 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $94.96 | 2023-2024 | |
| Amgen INC. | $83.60 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Paratek Pharmaceuticals, INC. | $41.62 | 2025 | Nuzyra, Xhance |
| Cipher Pharmaceuticals US LLC | $40.66 | 2025 | Natroba, Spinosad |
| Supernus Pharmaceuticals, INC. | $20.84 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $17.18 | 2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.91 | 2024 | Xifaxan, Trulance |
| Lundbeck LLC | $14.44 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.